Literature DB >> 12563578

A prospective, randomized, controlled trial of benzodiazepines and nitroglycerine or nitroglycerine alone in the treatment of cocaine-associated acute coronary syndromes.

Tim Honderick1, David Williams, David Seaberg, Robert Wears.   

Abstract

The purpose of the present study was to compare the use of lorazepam plus nitroglycerine (NTG) versus NTG alone in the reduction of cocaine induced chest pain in the emergency department. The secondary objective of the study was to help determine the safety of lorazepam in the treatment of cocaine- associated chest pain. The study was a prospective, randomized, single-blinded, controlled trial conducted at an university-affiliated urban emergency department (ED). All patients who presented with cocaine-associated chest pain were enrolled. Exclusion criteria included age greater than 45 years, documented coronary artery disease, chest pain of more than 72 hours duration, or pretreatment with nitroglycerin. Patients were given either sublingual nitroglycerine (SL NTG) (Group 1) or SL NTG plus 1 mg of lorazepam intravenously (Group 2) every 5 minutes for a total of 2 doses. Chest pain was recorded on an ordinal scale of 0 to 10 at baseline, and then at 5 minutes after each dose. Adverse reactions to medication were also recorded. Twenty-seven patients met the inclusion criteria and were enrolled in the study. The average age of these subjects was 34.1 years, and 67% were men. The NTG-only group consisted of 15 patients and the NTG-plus-lorazepam group consisted of 12 patients. Baseline mean chest-pain scores were 6.87 in Group 1 and 6.54 in Group 2, with no differences between groups. Five minutes after initial treatment, mean scores for the two groups were 5.2 and 3.9, respectively, with a difference in means of 1.24 (95% confidence interval [CI] -0.8-3.8). Five minutes after the second treatment, the mean scores were 4.6 and 1.5, respectively, with a difference in means of 3.1 (95% CI 1.2-5). Kruskal-Wallis testing showed a significant difference in pain relief between the two study groups (P =.003), with greater pain relief noted at 5 and 10 minutes in the NTG-plus-lorazepam group (P =.02 and P =.005, respectively). All patients in the study were admitted to the hospital, but no patient in either group had an acute myocardial infarction or cardiac complications in the ED. No adverse side effects were noted for either group. The early use of lorazepam with NTG was more efficacious than NTG alone, and appears to be safe in relieving cocaine-associated chest pain. Copyright 2003, Elsevier Science (USA). All rights reserved.)

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12563578     DOI: 10.1053/ajem.2003.50010

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  6 in total

Review 1.  Rethinking cocaine-associated chest pain and acute coronary syndromes.

Authors:  Jonathan B Finkel; Gregary D Marhefka
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

Review 2.  Treatment of patients with cocaine-induced arrhythmias: bringing the bench to the bedside.

Authors:  Robert S Hoffman
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

Review 3.  Best evidence topic report. Cocaine induced myocardial ischaemia: nitrates versus benzodiazepines.

Authors:  Priya Bhangoo; Andrew Parfitt; Tammy Wu
Journal:  Emerg Med J       Date:  2006-07       Impact factor: 2.740

Review 4.  Sympathomimetic Toxidromes and Other Pharmacological Causes of Acute Hypertension.

Authors:  Andrew King; Mirjana Dimovska; Luke Bisoski
Journal:  Curr Hypertens Rep       Date:  2018-02-24       Impact factor: 5.369

Review 5.  [Cardiac arrest under special circumstances].

Authors:  Carsten Lott; Anatolij Truhlář; Anette Alfonzo; Alessandro Barelli; Violeta González-Salvado; Jochen Hinkelbein; Jerry P Nolan; Peter Paal; Gavin D Perkins; Karl-Christian Thies; Joyce Yeung; David A Zideman; Jasmeet Soar
Journal:  Notf Rett Med       Date:  2021-06-10       Impact factor: 0.826

Review 6.  Clinical review: Major consequences of illicit drug consumption.

Authors:  Robert J Devlin; John A Henry
Journal:  Crit Care       Date:  2008-01-08       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.